Sanofi mulls insulin production in India amid rising emerging markets focus
This article was originally published in Scrip
Executive Summary
Sanofi is weighing plans to manufacture insulin in India, a move that is perhaps indicative of a significant strategic shift underway at the French giant as it gears to build on its diabetes franchise in emerging markets, where bulk of the disease is and will be concentrated.